Yi Lin

5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi et al. · Blood · 2023 · 228 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study.

Tao Jiang, Genfu Tang, Yi Lin et al. · PubMed · 2011 · 44 citations

Medicine, Neurology, Oncology +16

Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease

Na Zhou, Yi Lin, Xianghong Peng et al. · Lung Cancer · 2019 · 28 citations

Medicine, Oncology, Pathology +16

Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma

Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett et al. · Transplantation and Cellular Therapy · 2024 · 26 citations · Full text

Medicine, Oncology, Pharmacology +14

The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma

Kai Rejeski, Doris K. Hansen, Radhika Bansal et al. · Blood · 2022 · 25 citations

Medicine, Hematology, Oncology +17